Boothbay Fund Management
CRVS icon

Boothbay Fund Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Boothbay Fund Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,400
Closed -$45.8K – 1512
2025
Q1 		$45.8K Sell
14,400
-129,900
-90% -$612K ﹤0.01% 1287
2024
Q4 		$772K Buy
+144,300
New +$1.08M 0.02% 717

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boothbay Fund Management's CRVS Position: Q2 2022 in Review

Boothbay Fund Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2022, closing a stake of 48,211 shares — an estimated $79K sold.

Boothbay Fund Management first reported a position in CRVS in Q1 2021 and held it in 5 quarters. The position peaked at $366K in Q3 2021. 47 funds tracked by Wall St. Rank hold CRVS as of Q2 2022.

  • Boothbay Fund Management reported no remaining Corvus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 48,211 Corvus Pharmaceuticals shares in Q2 2022, an estimated $79K.
  • Boothbay Fund Management first reported a position in Corvus Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Boothbay Fund Management's Corvus Pharmaceuticals position peaked at $366K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.